Katana Biopharma

Katana Biopharma in its acquisition by Theratechnologies

Client

Katana Biopharma Inc.

Value

$8.1 million

Service

Mergers and Acquisitions

Date Closed

February 2019

Industry

Life Sciences

Lead Office

Montréal


On February 25, 2019, Theratechnologies acquired Katana Biopharma and its targeted oncology technology platform for $8.1 million. The acquisition is part of the companies’ long-term growth strategy to utilize Katana’s platform to continue development and execute their marketing strategies.

Katana Biopharma is a Montreal based biotech company that engages in the development of targeted oncology drugs.

Theratechnologies Inc., based out of Montreal, is a specialty pharmaceutical company, that addresses medical needs of HIV patients to promote healthy living and improve quality of life.

Osler, Hoskin & Harcourt LLP represented Katana Biopharma with a team led by Nathalie Beauregard (Corporate) that included Alain Fournier (Tax).


Team
Alain  Fournier

Alain Fournier

Partner, Taxation